Verition Fund Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.2M | Buy |
200,695
+194,655
| +3,223% | +$16.3M | 0.09% | 226 |
|
|
2026
Q1 | $484K | Sell |
6,040
-146,316
| -96% | -$12.1M | ﹤0.01% | 1603 |
|
|
2025
Q4 | $13M | Buy |
152,356
+83,476
| +121% | +$6.85M | 0.05% | 347 |
|
|
2025
Q3 | $5.36M | Sell |
68,880
-84,184
| -55% | -$6.58M | 0.02% | 1092 |
|
|
2025
Q2 | $12M | Buy |
153,064
+74,734
| +95% | +$5.57M | 0.05% | 434 |
|
|
2025
Q1 | $5.68M | Buy |
78,330
+72,910
| +1,345% | +$5.22M | 0.03% | 755 |
|
|
2024
Q4 | $401K | Sell |
5,420
-101,497
| -95% | -$7.1M | ﹤0.01% | 2609 |
|
|
2024
Q3 | $7.06M | Buy |
106,917
+83,157
| +350% | +$6.04M | 0.04% | 616 |
|
|
2024
Q2 | $2.19M | Buy |
23,760
+6,267
| +36% | +$555K | 0.01% | 1214 |
|
|
2024
Q1 | $1.67M | Sell |
17,493
-272
| -2% | -$22.8K | 0.01% | 1312 |
|
|
2023
Q4 | $1.35M | Buy |
+17,765
| New | +$1.24M | 0.01% | 1031 |
|
|
2023
Q2 | – | Sell |
-3,745
| Closed | -$326K | – | 2298 |
|
|
2023
Q1 | $310K | Sell |
3,745
-5,144
| -58% | -$404K | ﹤0.01% | 1506 |
|
|
2022
Q4 | $663K | Sell |
8,889
-34,425
| -79% | -$2.65M | 0.01% | 1110 |
|
|
2022
Q3 | $3.58M | Buy |
+43,314
| New | +$4.17M | 0.04% | 580 |
|
|
2021
Q4 | – | Sell |
-6,153
| Closed | -$718K | – | 2622 |
|
|
2021
Q3 | $697K | Buy |
+6,153
| New | +$702K | 0.01% | 1082 |
|
|
2021
Q2 | – | Sell |
-4,909
| Closed | -$411K | – | 1961 |
|
|
2021
Q1 | $411K | Buy |
+4,909
| New | +$415K | ﹤0.01% | 951 |
|
|
2020
Q4 | – | Sell |
-7,808
| Closed | -$623K | – | 1184 |
|
|
2020
Q3 | $623K | Sell |
7,808
-9,967
| -56% | -$778K | 0.01% | 493 |
|
|
2020
Q2 | $1.23M | Buy |
+17,775
| New | +$1.26M | 0.04% | 352 |
|
|
2020
Q1 | – | Sell |
-21,099
| Closed | -$1.64M | – | 752 |
|
|
2019
Q4 | $1.64M | Buy |
+21,099
| New | +$1.65M | 0.03% | 308 |
|
|
2019
Q3 | – | Sell |
-10,383
| Closed | -$639K | – | 1132 |
|
|
2019
Q2 | $639K | Buy |
+10,383
| New | +$628K | 0.02% | 578 |
|
|
2019
Q1 | – | Sell |
-3,942
| Closed | -$201K | – | 1153 |
|
|
2018
Q4 | $201K | Buy |
+3,942
| New | +$199K | 0.01% | 738 |
|
|
2018
Q3 | – | Sell |
-12,642
| Closed | -$613K | – | 1308 |
|
|
2018
Q2 | $613K | Buy |
+12,642
| New | +$590K | 0.04% | 612 |
|
|
2018
Q1 | – | Sell |
-33,861
| Closed | -$1.27M | – | 1177 |
|
|
2017
Q4 | $1.27M | Sell |
33,861
-7,920
| -19% | -$291K | 0.12% | 190 |
|
|
2017
Q3 | $1.52M | Buy |
+41,781
| New | +$1.59M | 0.12% | 166 |
|
|
2017
Q2 | – | Sell |
-40,023
| Closed | -$1.25M | – | 1025 |
|
|
2017
Q1 | $1.25M | Buy |
+40,023
| New | +$1.25M | 0.12% | 198 |
|
|
2016
Q4 | – | Sell |
-9,150
| Closed | -$368K | – | 1229 |
|
|
2016
Q3 | $368K | Sell |
9,150
-25,017
| -73% | -$942K | 0.04% | 653 |
|
|
2016
Q2 | $1.14M | Buy |
34,167
+17,817
| +109% | +$610K | 0.15% | 160 |
|
|
2016
Q1 | $481K | Buy |
16,350
+6,993
| +75% | +$193K | 0.08% | 333 |
|
|
2015
Q4 | $246K | Buy |
+9,357
| New | +$243K | 0.05% | 348 |
|
|
2015
Q1 | – | Sell |
-9,798
| Closed | -$208K | – | 420 |
|
|
2014
Q4 | $208K | Sell |
9,798
-14,646
| -60% | -$294K | 0.05% | 237 |
|
|
2014
Q3 | $416K | Buy |
24,444
+8,556
| +54% | +$135K | 0.06% | 290 |
|
|
2014
Q2 | $227K | Sell |
15,888
-1,026
| -6% | -$13.9K | 0.02% | 506 |
|
|
2014
Q1 | $209K | Buy |
+16,914
| New | +$195K | 0.03% | 387 |
|
|
2013
Q4 | – | Sell |
-20,454
| Closed | -$237K | – | 556 |
|
|
2013
Q3 | $237K | Buy |
+20,454
| New | +$239K | 0.04% | 401 |
|
Other funds holding EW
Verition Fund Management's EW Position: Q2 2026 in Review
Verition Fund Management increased its Edwards Lifesciences (EW) stake by 3,223% in Q2 2026, buying an estimated $16.3M and bringing the position to 200,695 shares worth $18.2M. The position accounts for 0.09% of the portfolio, ranked #226.
Verition Fund Management first reported a position in EW in Q3 2013 and has held it in 34 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Verition Fund Management held 200,695 shares of Edwards Lifesciences worth $18.2M as of Q2 2026.
- Verition Fund Management bought 194,655 Edwards Lifesciences shares in Q2 2026, an estimated $16.3M.
- Edwards Lifesciences made up 0.09% of Verition Fund Management's portfolio in Q2 2026, its #226 holding.
- Verition Fund Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 34 quarters since.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.